Acquisition Details

Sai Parenterals Limited has completed the acquisition of 60% equity stake in Prathyak Laboratories Private Limited, an operating research and development centre located at Genome Valley, Hyderabad. The acquisition was completed for Rs. 15 crore, funded from the unutilised net proceeds of the Company's initial public offering. Prathyak Laboratories has been renamed as Sai Prathyak Laboratories Private Limited and becomes a direct subsidiary of the Company.

Strategic Rationale

The acquisition replaces the greenfield research centre that the Company had originally intended to build, for which an allocation had been earmarked in the objects of the issue. Prathyak has been in operation for three years and brings:

  • 28 research scientists
  • Development pipeline of 150 SKUs across 86 molecules
  • Proven capability in lyophilised, liposomal and nano-based complex injectables
  • Expertise in oncology injectables

Operational Advantages

Acquisition of an operating platform rather than constructing one allows development work to begin immediately. It removes the construction cycle and the challenging task of assembling a scientific team of this calibre, which would have slowed the pace of a greenfield build.

Business Integration

Prathyak's development work supports the Company's injectable programme directly. Formulations developed at this R&D centre can be taken into commercial production as the Company's injectable capacity is expanded and upgraded, shortening the path from development to supply in regulated and semi-regulated markets.

The platform also supports the Group's Australian and New Zealand business through Noumed Pharmaceuticals, where renewed supply agreements carry a contractual commitment to introduce new products each year. Development for those launches can now be undertaken within the Group.

Future Ownership

The residual 40% may be acquired through a Right of First Refusal (ROFR) at the same valuation as the present transaction (Rs. 15 crore for 60% stake), to be funded from internal accruals, taking Prathyak to a wholly owned position.

Management Commentary

Mr. Anil Kumar Karusala, Chairman and Managing Director, stated: "Building a research centre from the ground up would have cost us a construction cycle and the time taken to assemble a scientific team. Prathyak gives us both on day one. The value of this acquisition lies in what it enables elsewhere in the Group. This is a further step in the growth plan we set out at the time of our listing: deeper integration across our own value chain, a faster route from development to commercial supply, and capability built inside the Group instead of with third parties."

Company Background

Sai Parenterals Limited is an integrated, IP-led pharmaceutical enterprise operating across two complementary verticals:

  • Contract development and manufacturing for Indian and multinational customers
  • Branded generic formulations sold domestically and exported into regulated and semi-regulated markets

Company portfolio includes:

  • 302 commercial products across nine therapeutic areas
  • 599 approved registrations and 67 dossiers under development
  • Six manufacturing facilities (five in India, one in Australia) with GMP, WHO-GMP, TGA-Australia and PIC/S accreditations
  • More than 50% of consolidated revenue contracted under long-term regulated-market agreements
  • Completed initial public offering in March 2026, listed on BSE and NSE on April 02, 2026